Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin vs SOC in Osteomyelitis
NCT02685033Phase 2Completed
- Sponsor
- Allergan
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in osteomyelitis (OM) comparing Dalbavancin with Standard of Care (2 arms). Primary endpoint: Percentage of Participants With Clinical Response at Day 42. Started Mar 2016; status: completed.
02
Drugs
dalbavancin
03
Conditions
osteomyelitis (OM)
Beyond the preview
Go deeper on NCT02685033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685033.